

# Savina Sn Nodari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5578254/publications.pdf>

Version: 2024-02-01

127  
papers

7,067  
citations

109137

35  
h-index

58464

82  
g-index

140  
all docs

140  
docs citations

140  
times ranked

10474  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Global Health and Economic Burden of Hospitalizations for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1123-1133.	1.2	1,640
2	Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. <i>European Heart Journal</i> , 2020, 41, 2083-2088.	1.0	716
3	Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. <i>European Heart Journal</i> , 2020, 41, 1821-1829.	1.0	434
4	Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance. <i>European Journal of Heart Failure</i> , 2008, 10, 188-195.	2.9	331
5	Differential Effects of $\beta$ -Blockers in Patients With Heart Failure. <i>Circulation</i> , 2000, 102, 546-551.	1.6	317
6	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
7	Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1248-1258.	1.2	220
8	Effects of n-3 Polyunsaturated Fatty Acids on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2011, 57, 870-879.	1.2	189
9	Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 194-202.	2.9	155
10	Serum levels of carbohydrate antigen 125 in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1805-1811.	1.2	149
11	The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. <i>European Journal of Heart Failure</i> , 2007, 9, 776-786.	2.9	139
12	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1401-1411.	2.9	119
13	Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 1999, 33, 943-950.	1.2	117
14	$\beta$ -Blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. <i>European Journal of Heart Failure</i> , 2003, 5, 621-627.	2.9	115
15	Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study. <i>Annals of Thoracic Surgery</i> , 2003, 76, 778-783.	0.7	111
16	n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. <i>Circulation</i> , 2011, 124, 1100-1106.	1.6	108
17	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. <i>International Journal of Cardiology</i> , 2013, 163, 206-211.	0.8	108
18	Marked improvement in left ventricular ejection fraction during long-term $\beta$ -blockade in patients with chronic heart failure: Clinical correlates and prognostic significance. <i>American Heart Journal</i> , 2003, 145, 292-299.	1.2	104

#	ARTICLE	IF	CITATIONS
19	The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programme. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 32, 724-729.	0.6	95
20	Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 750-758.	1.6	89
21	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , 2016, 18, 54-65.	2.9	73
22	Total Arterial Myocardial Revascularization With Composite Grafts Improves Results of Coronary Surgery in Elderly: A Prospective Randomized Comparison With Conventional Coronary Artery Bypass Surgery. <i>Circulation</i> , 2003, 108, 2911-33.	1.6	64
23	A rationale for the use of $\beta$ -blockers as standard treatment for heart failure. <i>American Heart Journal</i> , 2000, 139, 511-521.	1.2	62
24	The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy. <i>Cardiovascular Drugs and Therapy</i> , 2009, 23, 5-15.	1.3	60
25	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 76-84.	0.6	56
26	Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure. <i>Nutrition</i> , 2015, 31, 72-78.	1.1	56
27	Mediterranean diet impact on cardiovascular diseases. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 925-935.	0.6	55
28	Prognostic Significance of Serum Total Cholesterol and Triglyceride Levels in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013, 111, 574-581.	0.7	54
29	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	1.7	51
30	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014, 19, 135-152.	1.7	48
31	Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. <i>Annals of Hematology</i> , 2017, 96, 549-558.	0.8	48
32	Role of $\beta$ 1- and $\beta$ 2-adrenoceptor polymorphisms in heart failure: a case-control study. <i>European Heart Journal</i> , 2004, 25, 1534-1541.	1.0	46
33	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 429-437.	0.7	46
34	Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. <i>American Journal of Cardiology</i> , 2016, 117, 1231-1235.	0.7	38
35	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 440-451.	1.0	38
36	Effects of Oral Amino Acid Supplements on Functional Capacity in Patients with Chronic Heart Failure. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8, CMC.S14016.	0.6	37

#	ARTICLE	IF	CITATIONS
37	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2015, 115, 790-796.	0.7	37
38	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	1.6	34
39	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 281-291.	2.9	33
40	Role of $\beta_1$ - and $\beta_2$ -adrenergic receptor polymorphisms and their combination in heart failure: A case-control study. <i>European Journal of Heart Failure</i> , 2006, 8, 131-135.	2.9	29
41	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. <i>European Journal of Internal Medicine</i> , 2020, 71, 23-31.	1.0	29
42	Effects of Spironolactone on Long-term Mortality and Morbidity in Patients With Heart Failure and Mild or No Symptoms. <i>American Journal of the Medical Sciences</i> , 2014, 347, 271-276.	0.4	23
43	Preventing antineoplastic drug-related cardiomyopathy. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e64-e75.	0.6	23
44	Redefining biomarkers in heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 237-253.	1.7	23
45	Prevention and management of chronic heart failure in patients at risk. <i>American Journal of Cardiology</i> , 2003, 91, 10-17.	0.7	20
46	Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly? <i>European Journal of Cardio-thoracic Surgery</i> , 2003, 23, 657-664.	0.6	20
47	Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus. <i>European Journal of Heart Failure</i> , 2003, 5, 803-809.	2.9	20
48	CA 125 Tumoral Marker Plasma Levels Relate to Systolic and Diastolic Ventricular Function and to the Clinical Status of Patients with Chronic Heart Failure. <i>Echocardiography</i> , 2008, 25, 955-960.	0.3	20
49	Vericiguat for Heart Failure with Reduced Ejection Fraction. <i>Current Cardiology Reports</i> , 2021, 23, 144.	1.3	19
50	Role of biomarkers in monitoring antineoplastic cardiotoxicity. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e27-e34.	0.6	18
51	Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 942-951.	0.8	17
52	Lack of association of coeliac disease with idiopathic and ischaemic dilated cardiomyopathies. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 692-695.	0.6	16
53	$\beta$ -Blockade in Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 3-14.	1.0	15
54	High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion. <i>Internal and Emergency Medicine</i> , 2009, 4, 309-313.	1.0	14

#	ARTICLE	IF	CITATIONS
55	Nitric oxide and cardiovascular risk factors. <i>Heart International</i> , 2007, 3, 18.	0.4	14
56	Acute Heart Failure With Low Cardiac Output: Can We Develop a Short-term Inotropic Agent That Does Not Increase Adverse Events?. <i>Current Heart Failure Reports</i> , 2010, 7, 100-109.	1.3	13
57	Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. <i>International Journal of Cardiology</i> , 2022, 350, 62-68.	0.8	13
58	Six-year prognosis of diabetic patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2012, 42, 376-383.	1.7	12
59	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 117, 340-346.	0.7	12
60	Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial. <i>American Heart Journal</i> , 2020, 224, 129-137.	1.2	12
61	Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan. <i>ESC Heart Failure</i> , 2022, 9, 1107-1117.	1.4	12
62	Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. <i>Internal and Emergency Medicine</i> , 2011, 6, 37-44.	1.0	10
63	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 799-809.	0.6	10
64	Right heart dysfunction. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 613-623.	0.6	10
65	New Targets in Heart Failure Drug Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665797.	1.1	10
66	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. <i>European Journal of Internal Medicine</i> , 2022, 102, 8-16.	1.0	10
67	Persistence of left superior vena cava, absence of coronary sinus and cerebral ictus. <i>International Journal of Cardiology</i> , 2008, 126, e39-e41.	0.8	9
68	Current treatment in acute and chronic cardio-renal syndrome. <i>Heart Failure Reviews</i> , 2011, 16, 583-594.	1.7	9
69	Management of heart failure in the new era. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 569-580.	0.6	9
70	Impact of 2020 SARS-CoV-2 outbreak on telemedicine management of cardiovascular disease in Italy. <i>Internal and Emergency Medicine</i> , 2021, 16, 1191-1196.	1.0	9
71	Clinical Impact of Renal Dysfunction in Heart Failure. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 186-199.	0.5	9
72	Relation of Serum Magnesium Levels and Postdischarge Outcomes in Patients Hospitalized for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013, 112, 1763-1769.	0.7	8

#	ARTICLE	IF	CITATIONS
73	A new educational program in heart failure drug development. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 411-421.	0.6	8
74	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , 2022, 27, 1147-1163.	1.7	8
75	Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 718.	0.5	8
76	Effects of the Covid-19 pandemic on the formation of fellows in training in cardiology. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 711-715.	0.6	7
77	Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 182-187.	0.6	6
78	Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2010, 3, 51.	0.8	6
79	The left ventricle as a mechanical engine. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 214-220.	0.6	6
80	An expression of concern on research during the Covid-19 pandemic. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 838-839.	0.6	6
81	Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 569-78.	0.9	6
82	Non-compaction of the ventricular myocardium. <i>Heart International</i> , 2006, 2, 178.	0.4	5
83	Acute heart failure syndromes: assessment and reconstructing the heart. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 258-263.	0.6	5
84	Maximal and Submaximal Exercise Testing in Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 32, S36-S45.	0.8	4
85	Beta Blockers in Heart Failure: Issues in Management of Individual Patients. <i>Heart Failure Reviews</i> , 1999, 4, 65-78.	1.7	3
86	Current guidelines in the pharmacological management of chronic heart failure.. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004, 5, S11.	1.0	3
87	Î²-blocker therapy of heart failure: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 289-298.	0.9	3
88	Improved graft patency rates and mid-term outcome of diabetic patients undergoing total arterial myocardial revascularization. <i>Heart International</i> , 2006, 2, 136.	0.4	3
89	The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. <i>Heart International</i> , 2007, 3, 12.	0.4	3
90	Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations. <i>General Pharmacology</i> , 1996, 27, 1255-1259.	0.7	2

#	ARTICLE	IF	CITATIONS
91	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. <i>Heart Failure Reviews</i> , 2022, 27, 135-145.	1.7	2
92	Endothelial damage due to air pollution. <i>Heart International</i> , 2006, 2, 115.	0.4	2
93	Selective or nonselective $\beta$ -adrenergic blockade in patients with congestive heart failure. <i>Current Cardiology Reports</i> , 2000, 2, 252-257.	1.3	1
94	Improved Graft Patency Rates and Mid-Term Outcome of Diabetic Patients Undergoing Total Arterial Myocardial Revascularization. <i>Heart International</i> , 2006, 2, 182618680600200.	0.4	1
95	Biomarkers in Acute Heart Failure Syndromes – Are They Fulfilling Their Promise?. <i>Cardiology</i> , 2011, 120, 19-21.	0.6	1
96	Impact of Multidisciplinary Personalized Disease Management Program on Readmission Rate after Discharge in Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2014, 20, S112.	0.7	1
97	Questioning the Associations of $\omega$ -3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , 2018, 3, 781.	3.0	1
98	The oldest Society of Cardiology in Italy meets the ESC. <i>European Heart Journal</i> , 2020, 41, 2055-2058.	1.0	1
99	Comprehensive heart failure assessment: A challenge to modify the course of heart failure. Author's reply. <i>European Journal of Internal Medicine</i> , 2020, 74, 125-126.	1.0	1
100	Quick response code applications in medical and cardiology settings: a systematic scoping review. <i>European Heart Journal Digital Health</i> , 2021, 2, 336-341.	0.7	1
101	The study of left ventricular diastolic function by Doppler echocardiography: the essential for the clinician. <i>Heart International</i> , 2007, 3, 42.	0.4	1
102	The Role of Beta Blockade in Heart Failure. <i>European Cardiology Review</i> , 2005, 1, 1.	0.7	1
103	Genetic test for Mendelian fatigue and muscle weakness syndromes. <i>Acta Biomedica</i> , 2020, 91, e2020001.	0.2	1
104	Combined invasive and noninvasive study of left ventricular systolic and diastolic function following acute administration of cicloprolol to subjects with normal cardiac function. <i>Cardiovascular Drugs and Therapy</i> , 1992, 6, 513-517.	1.3	0
105	Endothelial Damage Due to Air Pollution. <i>Heart International</i> , 2006, 2, 182618680600200.	0.4	0
106	Managing heart failure in the very old. <i>Aging Health</i> , 2006, 2, 253-275.	0.3	0
107	Role of Worsening Renal Function in Patients Hospitalised for Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2007, 13, S168.	0.7	0
108	Integrated Heart Failure Management in the Patient with Heart Failure Caused by Left Ventricular Systolic Dysfunction. , 0, , 1-30.		0

#	ARTICLE	IF	CITATIONS
109	Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article "The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy". Cardiovascular Drugs and Therapy, 2009, 23, 335-336.	1.3	0
110	BETA-1 ADRENERGIC RECEPTOR GENE POLIMORPHISM IN HEART FAILURE: A GENDER SPECIFIC CLINICAL AND PROGNOSTIC ROLE?. Journal of the American College of Cardiology, 2010, 55, A131.E1227.	1.2	0
111	OP-001 PROGNOSTIC STRATIFICATION IN DIABETIC PATIENTS ADMITTED FOR ACUTE CORONARY SYNDROME. International Journal of Cardiology, 2010, 140, S1.	0.8	0
112	OP-006 PREDICTORS OF FETAL-MATERNAL OUTCOMES IN PREGNANT ASYMPTOMATIC WOMEN WITH CARDIOVASCULAR RISK FACTORS. International Journal of Cardiology, 2010, 140, S2-S3.	0.8	0
113	OP-095 PROGNOSTIC ROLE OF MYOCARDIAL PERFORMANCE INDEX (MPI) AND CA 125 IN PATIENTS WITH CHRONIC HEART FAILURE. International Journal of Cardiology, 2010, 140, S27-S28.	0.8	0
114	OP-096 PROGNOSTIC ROLE OF PHARMACOLOGICAL AND REVASCULARIZATION TREATMENT IN DIABETIC ISCHEMIC PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION. International Journal of Cardiology, 2010, 140, S28.	0.8	0
115	Prognostic Value of Serial Clinical, Laboratory and Ecocardiographic Tests in Ambulatory Patients with Chronic Heart Failure. Journal of Cardiac Failure, 2011, 17, S83.	0.7	0
116	Hospitalizations for Heart Failure. Heart Failure Clinics, 2013, 9, xi-xii.	1.0	0
117	SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL. Journal of the American College of Cardiology, 2013, 61, E631.	1.2	0
118	PROGNOSTIC ROLE OF ATRIAL FIBRILLATION AND HEART RATE CONTROL IN CHRONIC HEART FAILURE PATIENTS. Journal of the American College of Cardiology, 2013, 61, E735.	1.2	0
119	Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy. Journal of Cardiac Failure, 2014, 20, S26-S27.	0.7	0
120	SAFE MULTIDISCIPLINARY MANAGEMENT OF NEW THERAPIES: THE RITMO PROJECT (REAL TIME CONTINUOUS) Tj	1.2	0
121	PROGNOSTIC VALUE OF MYOCARDIAL FIBROSIS ASSESSED BY CARDIAC MAGNETIC RESONANCE IN PATIENT WITH IDIOPATHIC DILATED CARDIOMYOPATHY WITH LEFT VENTRICUAL SYSTOLIC DYSFUNCTION. Journal of the American College of Cardiology, 2017, 69, 2117.	1.2	0
122	The Prevention of Sudden Death: New Perspectives. , 2007, , 205-213.		0
123	Endocannabinoids and cardiovascular prevention: real progress?. Heart International, 2007, 3, 27.	0.4	0
124	Anemia and heart failure: a cause of progression or only a consequence?. Heart International, 2007, 3, 1.	0.4	0
125	Heart failure and cardiorenal syndrome: a case report. Clinical Management Issues, 2011, 5, 27-35.	0.3	0
126	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. Heart Failure Reviews, 2022, , .	1.7	0



#	ARTICLE	IF	CITATIONS
127	Biventricular evaluation of gliflozines effects in chronic heart failure patients function (begin-HF) Tj ETQq1 1 0,784314 ggBT /Over	0,0	0,0